Calciphylaxis

Diagnosis and clinical features

Matsuhiko Hayashi

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Calciphylaxis is a relatively rare disease, observed mainly in patients on dialysis, associated with high mortality rates, and characterized by painful skin ulceration. The pathogenesis of calciphylaxis is virtually unknown, although several risk factors, including warfarin therapy, hypoalbuminemia, and disturbances in calcium-phosphate metabolism, have been reported. The prevalence of calciphylaxis in Japan is likely to be less than 1:10,000 dialysis patients per year based on our nationwide survey in 2009. However, the results of the survey also showed that about 60 % of nephrologists in Japan are not familiar with the disease itself and it is highly likely that calciphylaxis is being overlooked. To facilitate recognition of calciphylaxis, we have proposed diagnostic criteria. At present, there is no specific therapy for calciphylaxis and general supportive measures, especially antibiotics for the accompanying infection and wound care, are important. Recently, sodium thiosulfate has been increasingly used to treat calciphylaxis and its efficacy should be evaluated by large clinical trials.

Original languageEnglish
Pages (from-to)498-503
Number of pages6
JournalClinical and Experimental Nephrology
Volume17
Issue number4
DOIs
Publication statusPublished - 2013 Aug

Fingerprint

Calciphylaxis
Dialysis
Japan
Hypoalbuminemia
Wound Infection
Warfarin
Rare Diseases
Clinical Trials
Anti-Bacterial Agents
Skin
Mortality

Keywords

  • Calciphylaxis
  • Hemodialysis
  • Sodium thiosulfate
  • Warfarin

ASJC Scopus subject areas

  • Nephrology
  • Physiology
  • Physiology (medical)

Cite this

Calciphylaxis : Diagnosis and clinical features. / Hayashi, Matsuhiko.

In: Clinical and Experimental Nephrology, Vol. 17, No. 4, 08.2013, p. 498-503.

Research output: Contribution to journalArticle

Hayashi, Matsuhiko. / Calciphylaxis : Diagnosis and clinical features. In: Clinical and Experimental Nephrology. 2013 ; Vol. 17, No. 4. pp. 498-503.
@article{6375d0bd201d42edae9738eccdf979e6,
title = "Calciphylaxis: Diagnosis and clinical features",
abstract = "Calciphylaxis is a relatively rare disease, observed mainly in patients on dialysis, associated with high mortality rates, and characterized by painful skin ulceration. The pathogenesis of calciphylaxis is virtually unknown, although several risk factors, including warfarin therapy, hypoalbuminemia, and disturbances in calcium-phosphate metabolism, have been reported. The prevalence of calciphylaxis in Japan is likely to be less than 1:10,000 dialysis patients per year based on our nationwide survey in 2009. However, the results of the survey also showed that about 60 {\%} of nephrologists in Japan are not familiar with the disease itself and it is highly likely that calciphylaxis is being overlooked. To facilitate recognition of calciphylaxis, we have proposed diagnostic criteria. At present, there is no specific therapy for calciphylaxis and general supportive measures, especially antibiotics for the accompanying infection and wound care, are important. Recently, sodium thiosulfate has been increasingly used to treat calciphylaxis and its efficacy should be evaluated by large clinical trials.",
keywords = "Calciphylaxis, Hemodialysis, Sodium thiosulfate, Warfarin",
author = "Matsuhiko Hayashi",
year = "2013",
month = "8",
doi = "10.1007/s10157-013-0782-z",
language = "English",
volume = "17",
pages = "498--503",
journal = "Clinical and Experimental Nephrology",
issn = "1342-1751",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Calciphylaxis

T2 - Diagnosis and clinical features

AU - Hayashi, Matsuhiko

PY - 2013/8

Y1 - 2013/8

N2 - Calciphylaxis is a relatively rare disease, observed mainly in patients on dialysis, associated with high mortality rates, and characterized by painful skin ulceration. The pathogenesis of calciphylaxis is virtually unknown, although several risk factors, including warfarin therapy, hypoalbuminemia, and disturbances in calcium-phosphate metabolism, have been reported. The prevalence of calciphylaxis in Japan is likely to be less than 1:10,000 dialysis patients per year based on our nationwide survey in 2009. However, the results of the survey also showed that about 60 % of nephrologists in Japan are not familiar with the disease itself and it is highly likely that calciphylaxis is being overlooked. To facilitate recognition of calciphylaxis, we have proposed diagnostic criteria. At present, there is no specific therapy for calciphylaxis and general supportive measures, especially antibiotics for the accompanying infection and wound care, are important. Recently, sodium thiosulfate has been increasingly used to treat calciphylaxis and its efficacy should be evaluated by large clinical trials.

AB - Calciphylaxis is a relatively rare disease, observed mainly in patients on dialysis, associated with high mortality rates, and characterized by painful skin ulceration. The pathogenesis of calciphylaxis is virtually unknown, although several risk factors, including warfarin therapy, hypoalbuminemia, and disturbances in calcium-phosphate metabolism, have been reported. The prevalence of calciphylaxis in Japan is likely to be less than 1:10,000 dialysis patients per year based on our nationwide survey in 2009. However, the results of the survey also showed that about 60 % of nephrologists in Japan are not familiar with the disease itself and it is highly likely that calciphylaxis is being overlooked. To facilitate recognition of calciphylaxis, we have proposed diagnostic criteria. At present, there is no specific therapy for calciphylaxis and general supportive measures, especially antibiotics for the accompanying infection and wound care, are important. Recently, sodium thiosulfate has been increasingly used to treat calciphylaxis and its efficacy should be evaluated by large clinical trials.

KW - Calciphylaxis

KW - Hemodialysis

KW - Sodium thiosulfate

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=84883297943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883297943&partnerID=8YFLogxK

U2 - 10.1007/s10157-013-0782-z

DO - 10.1007/s10157-013-0782-z

M3 - Article

VL - 17

SP - 498

EP - 503

JO - Clinical and Experimental Nephrology

JF - Clinical and Experimental Nephrology

SN - 1342-1751

IS - 4

ER -